Patents by Inventor John F. Oram

John F. Oram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE
    Publication number: 20170016924
    Abstract: The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 19, 2017
    Applicant: University of Washington
    Inventors: Jay W. Heinecke, John F. Oram
  • Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
    Patent number: 8541236
    Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: September 24, 2013
    Assignees: University of Washington, The Children's Hospital & Research Center At Oakland
    Inventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
  • METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE
    Publication number: 20100297680
    Abstract: The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 25, 2010
    Applicant: University of Washington
    Inventors: Jay W. Heinecke, John F. Oram
  • Methods for assessing the risk for development of cardiovascular disease
    Patent number: 7749729
    Abstract: The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: July 6, 2010
    Assignee: University of Washington
    Inventors: Jay W. Heinecke, John F. Oram
  • Methods for Assessing the Risk for Development of Cardiovascular Disease
    Publication number: 20080261250
    Abstract: The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
    Type: Application
    Filed: July 19, 2005
    Publication date: October 23, 2008
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Jay W. Heinecke, John F. Oram
  • COMPOSITIONS AND METHODS OF USE FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20080234192
    Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.
    Type: Application
    Filed: December 6, 2007
    Publication date: September 25, 2008
    Applicants: WASHINGTON, UNIVERSITY OF, CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND
    Inventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
  • Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
    Patent number: 6835563
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: December 28, 2004
    Assignee: CV Therapeutics
    Inventors: Richard M. Lawn, David Wade, Michael Garvin, John F. Oram